CN104877972B - A kind of dual-gene gene-deleted strain of recombinant porcine pseudorabies poison gE/gI and its application - Google Patents
A kind of dual-gene gene-deleted strain of recombinant porcine pseudorabies poison gE/gI and its application Download PDFInfo
- Publication number
- CN104877972B CN104877972B CN201510246482.3A CN201510246482A CN104877972B CN 104877972 B CN104877972 B CN 104877972B CN 201510246482 A CN201510246482 A CN 201510246482A CN 104877972 B CN104877972 B CN 104877972B
- Authority
- CN
- China
- Prior art keywords
- vaccine
- gene
- porcine pseudorabies
- strain
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000009305 pseudorabies Diseases 0.000 title claims abstract description 19
- 239000002574 poison Substances 0.000 title description 11
- 231100000614 poison Toxicity 0.000 title description 11
- 229960005486 vaccine Drugs 0.000 claims abstract description 62
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 239000000427 antigen Substances 0.000 claims abstract description 10
- 108091007433 antigens Proteins 0.000 claims abstract description 10
- 102000036639 antigens Human genes 0.000 claims abstract description 10
- 239000003223 protective agent Substances 0.000 claims abstract description 8
- 230000003612 virological effect Effects 0.000 claims abstract description 7
- 230000001018 virulence Effects 0.000 claims abstract description 6
- 230000002238 attenuated effect Effects 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960004854 viral vaccine Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 abstract description 57
- 241000699670 Mus sp. Species 0.000 abstract description 11
- 238000012217 deletion Methods 0.000 abstract description 3
- 230000037430 deletion Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 230000002068 genetic effect Effects 0.000 abstract description 3
- 230000000680 avirulence Effects 0.000 abstract description 2
- 230000005571 horizontal transmission Effects 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 description 37
- 238000000034 method Methods 0.000 description 17
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 10
- 241000282898 Sus scrofa Species 0.000 description 9
- 101150030521 gI gene Proteins 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000003501 vero cell Anatomy 0.000 description 8
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 101150072564 gE gene Proteins 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000009781 safety test method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001673669 Porcine circovirus 2 Species 0.000 description 1
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 241000723848 Tobamovirus Species 0.000 description 1
- 241000710914 Totivirus Species 0.000 description 1
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 1
- 101150092158 US8 gene Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000002133 sample digestion Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940124973 vaccine residual Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
It is an object of the invention to provide a kind of porcine pseudorabies virus vaccine; it is made up of antigen and protective agent, wherein antigen includes the attenuated viral strains made of the porcine pseudorabies virus strain that deposit number is CGMCC No.10266 carries out after virulence gene gE and gI missing.Vaccine prepared by the present invention can effectively prevent porcine pseudorabies; and as the porcine pseudorabies virus of antigen it is gene-deleted strain; infected by horizontal transmission in Mice Body continuous passage; it is showed no virulence and returns strong phenomenon; genetic stability; meet porcine pseudorabies virus deletion of vaccine strain avirulence and return strong standard, manufactured vaccine can provide effective immunoprotection, have good commercialized development prospect.
Description
Technical field
The invention belongs to veterinary vaccines preparing technical field, and in particular to a kind of recombinant porcine pseudorabies poison gE/gI is biradical
Because of gene-deleted strain and its application.
Background technology
Porcine pseudorabies virus PRV (Pseudorabies virus) belongs to herpetoviridae a herpesviral subfamilies bubbles
Tobamovirus herpesvirus suis I types, pig are unique natural reservoir (of bird flu viruses) of the virus, cause pig pseudoabies (Pseudorabies,
PR).The disease is in outbreak of epidemic in swinery more, main harm sow group, causes Sow abortion or vertical transmission to be caused just to piglet
Cub's pig mortality, the pig industry to China or even the whole world bring huge economic loss.Having for treatment PR is there is no at present
Medicine is imitated, therefore vaccine inoculation turns into the generation of the control disease and popular major measure.Most popular vaccine master in the world
If PRV Bartha-K61 strain vaccines, but China's pseudorabies pestilence present situation was that the existing vaccine can not be complete in recent years
The new popular PRV of full guard attack, certain economic loss is caused to immune pig farm.Accordingly, it is desirable to provide cri dernier cri is malicious
Vaccine prepared by strain just turns into the study hotspot of porcine pseudorabies virus disease prevention and control field.
The content of the invention
It is an object of the invention to provide a kind of dual-gene gene-deleted strains of recombinant porcine pseudorabies poison gE/gI and its application, i.e., by
The vaccine that the gene-deleted strain of the porcine pseudorabies virus filtered out is prepared as antigen, vaccine of the invention is to currently a popular
The attack of porcine pseudorabies virus can provide good immune protection effectiveness.
Present invention firstly provides a kind of PRV gene-deleted strain, it by deposit number is CGMCC to be
No.10266 porcine pseudorabies virus strain is carried out made of after gE and gI gene delections.
Another aspect of the invention provides application of the above-mentioned PRV gene-deleted strain in vaccine is prepared；
Another aspect of the present invention provides a kind of porcine pseudorabies virus vaccine, is made up of antigen and protective agent, wherein
Antigen includes above-mentioned PRV gene-deleted strain.
Protective agent therein is the viral vaccine protective agent that uses at present, a kind of its specific composition of embodiment be sucrose and
The aqueous solution of gelatin, its mass percent final concentration in vaccine is respectively 20% and 4.8%.
Antibiotic, penicillin, streptomysin final concentration of 200 units/ml are added in above-mentioned vaccine；
Vaccine prepared by the present invention can effectively prevent porcine pseudorabies, and be base as the porcine pseudorabies virus of antigen
Because of gene-deleted strain, infected by horizontal transmission in Mice Body continuous passage, be showed no virulence and return strong phenomenon, genetic stability, meet
Porcine pseudorabies virus deletion of vaccine strain avirulence returns strong standard, and manufactured vaccine can provide effective immunoprotection, tool
There is good commercialized development prospect.
Embodiment
The invention will now be further described with reference to specific embodiments, and one of ordinary skill in the art is in the technology of the present invention
On the basis of scheme, method and step commonly used in the art can be selected, is not limited solely to the specific of description of the invention embodiment
Record.
Embodiment 1：The seed selection of CGMCC No.10266 porcine pseudorabies virus strains
In recent years, for the multiple pig farms in China all there occurs pseudoabies, wherein most is kind of a pig farm, and before the swinery that falls ill
Pseudo- rabies vaccine is injected, thus it is speculated that the virus of infection is made a variation；Therefore pseudorabies have been carried out from morbidity swinery
The screening of virus.
Morbidity haslet sample is taken, including：Heart, liver, lungs, spleen, tonsillotome and lymph node etc..By internal organ sample
With PBS (0.1M, pH7.2) with V/V1:5 are made homogenate, multigelation 3 times, 3000r/min centrifugation 15min, take in supernatant and add
Dual anti-, 1h is made in 37 DEG C of senses, degerming through 0.22 μm of membrane filtration.1ml virus filtrates are taken to be inoculated in the Vero cells for growing up to individual layer, it is blind
Pass three generations, observation cytopathy (CPE).The cell culture fluid that will appear from CPE carries out Plaque-purified, virus packing guarantor after purification
Deposit to -70 DEG C it is standby, and determine viral level.Choose the porcine pseudorabies virus QD strain (chimpanzee agents as vaccine development
Porcine herpesvirus Type I) it has been preserved in Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 on March 6th, 2015
Number China Committee for Culture Collection of Microorganisms's common micro-organisms center of Institute of Microorganism, Academia Sinica, deposit number
For CGMCC No.10266.
The strain screened for the present invention enters performing PCR detection, and blast analyses are carried out after sequencing, it is found that deposit number is
The gE genes of CGMCC No.10266 porcine pseudorabies virus with 2012 after report porcine pseudorabies virus it is relative
Although there is the difference of at least two amino acid in the sequence answered, but affiliation is nearer, be in a relatively independent branch
In, with the strain affiliation that separates before farther out.And the strain with separating recently has identical characterization of molecules, i.e., in gE bases
Respectively there is the insertion of 1 aspartic acid cause the 48th and 492-496 positions, and other reports also confirm that also this point.And it is previously separated
To strain only have position insertion amino acid individually, the overwhelming majority is not inserted into.Therefore above-mentioned difference can speculated just
It is where the reason for causing existing porcine pseudorabies virus immune effect of vaccine bad.
After the strain makees 100 times of dilutions, neutralized with equivalent porcine pseudorabies virus antiserum, virus can be by hyper-immune serum
Specificity neutralizes；And with equivalent pig parvoviral, swine influenza virus, CSFV, porcine circovirus 2 type, pig breeding with breathing
In syndrome virus, Porcine epidemic diarrhea virus and transmissible gastro-enteritis virus antiserum and group, cell present obvious thin
Born of the same parents' lesion, it is seen that the virus-specific is good.After vaccine immune BALB/C mouse prepared by the strain, the death of mouse can be reduced
Rate.
Embodiment 2：The structure of the dual-gene gene-deleted strains of recombinant porcine pseudorabies poison gE/gI
The DNA of the separation strains is extracted from the porcine pseudorabies virus (CGMCC No.10266) of separation, using gene work
The method of journey carries out the missing of virulence gene gE and gI gene to the separation strains, and is named as PRV/ after being saved on cell
gE-/gI-, numerous poison, add after protective agent as seed poison.Embodiment is as follows：
1PCR primers
With reference to PRV whole genome sequences (BK001744), serial primer is voluntarily synthesized, amplification is respectively intended to and is located at US7
(gI) the left arm fragment (L) available for homologous recombination of gene and US8 (gE) genes both sides (gI containing part and gE genes) and the right side
Arm pieces section (R).Wherein L includes part US6 genes and part gI genes, and R includes part gE genes, whole US9 genes and portion
Divide US2 genes.Design primer amplification EGFP and EGFP eukaryotic expression boxes simultaneously in addition, and for identifying drawing for gene delection
Thing.The size of primer sequence and expected PCR primer is shown in Table 1.
Table 1：The primer used in this research
The structure of 2gE and gI gene transfer vectors
Using PRV QD pnca genes groups as template, using primer gEILF/GEILR and gEIRF/GEIRR, position is amplified respectively
Sequence (gE containing part and gI genes) in gE and gI both sides recombinates the one of arm gEIL, gEIR, wherein gEIL, gEIR as left and right
End is respectively provided with a loxP site.Enter performing PCR and digestion identification to it after being cloned into pMD19-T, identify correct rear survey
Sequence, double digestion is carried out using Hind III and Pst I to correct positive colony T-gEIL is sequenced, the fragment is cloned into together
On the pBluescript SK carriers of sample digestion processing, using Spe I and Xba I respectively to the recombinant plasmid after identifying correctly
Double digestion is carried out with the recombinant plasmid vector for being connected with right side homology arm, the linearisation restructuring matter containing left side homology arm is separately recovered
Grain and right side homology arm, the two is attached.PCR and digestion are identified.Send sequencing after identification is correct, sequencing result is correct
Be named as pSKgEILR.
Using pCDNA3.1-EGFP plasmids as template, EGFP reading frames are expanded using primer EorfF/EorfR, are connected into eucaryon
Expression vector pVAX1, the eukaryotic expression containing EGFP is amplified using primer cassetteF/cassetteF after identifying correctly
Box, pMD19-T carriers are connected into, pMDEV is named as after identification is correct.
Double digestion is carried out to pMDEV using Pst I and Spe I, eukaryotic expression box is reclaimed, is connected into same double digestion
PSKgEILR, correct rear as gE and gI gene transfer vectors are identified, are named as pSKgE-EGFP.
The structure of 3gE and gI gene delection strain virus and purifying rescue
3.1 transfection
Recombinant virus rescue is carried out in six porocyte culture plates, is transfected when Vero cells cover with 90%.Take PRV
The μ g of QD pnca genes group 3, after being mixed with 1 μ g transferring plasmids pSKgE-EGFP, cotransfection according to a conventional method, method detailed referring to
LipofectamineTM2000 specifications.Set the only control group containing transferring plasmid simultaneously.
3.2 identification
PRV QD pnca genes groups are with after pSKgE-EGFP cotransfections 48h, observing transfectional cell lesion formational situation and fluorescence
Protein expression situation.In the generation of blind passage two after transfectional cell cracking, still there are cytopathy and green fluorescence, tentatively judge that recombinant virus is saved
Rescue success.Recombinant virus is identified through plaque purification and PCR, is named as PRV/gE-/gI-/EGFP。
The rejecting of 3.3 gene-deleted strain reporter genes
Reporter gene EGFP is rejected using the site-specific recombination of Cre-loxP System-mediateds.10 μ g are taken through Cre
The DNA that ferment treatment is crossed, using calcium phosphate procedure transfected Vero cells, put 37 DEG C of CO22-3d is cultivated in incubator, treats that cell produces
Virus liquid is harvested during raw 80% lesion.Virus liquid multigelation is taken into supernatant afterwards three times, being inoculated in 24 orifice plates by 2uL/ holes grows up to
The Vero cells of individual layer, low melting-point agarose is spread when Jian begins and cytopathy occurs, picking does not have fluorescence under fluorescence microscope
Plaque.Purified virus so repeatedly, until all virus plaques, without the prominent light of green, it is PRV/ to name the gene-deleted strain
gE-/gI-。
3.4PRV/gE-/gI-Identification
Extract PRV/gE-/gI-Genomic DNA, enter performing PCR with primer gEIF/gEIR and primer gBF/gBR and expand, identification
Whether the viral gene interior segments of rescue lack, if parent plant, PRV/gE-/gI-/ EGFP gene group DNA is as control.
The genetic stability detection of 4 recombinant viruses
The primary PRV/gE obtained will be screened-/gI-Recombinant virus continuous passage on Vero cells, every 5 generation extraction infection
Cell STb gene, carry out the PCR detections of lack part gene.
5PRV/gE-/gI-Seed culture of viruses safety testing
With PBS by 10 times of antigen diluent, 100 grams of intramuscular inoculation mouse four, every 0.2mL, observe 14 days, its react or
Dead must not exceed two.
6PRV/gE-/gI-Immune efficacy detection
The BALB/C mice of 6 week old is randomly divided into 3 groups, every group 5 and weighed, vaccinates a plant Bartha- respectively
K61, gene-deleted strain PRV/gE-/gI-And DMEM.The μ L DMEM of every injection of control group 100, other two groups of hindlimb muscles injections
104TCID50The vaccine of viral dosage.The clinical symptoms of daily observation mouse, whether there is One's spirits are drooping, apocleisis, itch, shake after immune
Quiver, 21d weighs again, and in 14d, 21d tail vein blood, serum is separated, with the coated ELISA of PRV QD strain totivirus
Plate detects antibody level of serum.21d attacks poison with PRV QD strains after immune, with 104TCID50Each test group of dose inoculation and control
Group, injected using hindlimb muscle, Continuous Observation 14d after virus inoculation.
7 results
Using PRV QD strain virus as template, gE and gI gene transfer vectors are successfully obtained；It is then that it is same with PRV genomes
Source recombinates, and successfully saves and is purified into gE the and gI gene delection strain virus containing EGFP marker gene；Using Cre recombinases
After removing EGFP marker gene, gE the and gI gene delection strain virus for not containing EGFP marker gene is successfully saved and is purified into
(PRV/gE-/gI-)。
The PRV/gE obtained will be screened-/gI-The continuous passage on Vero cells of primary recombinant virus, every 5 generation extraction infection
Cell STb gene, the PCR testing results of lack part gene show that the size of gene is the size after deletion fragment, show this
Recombinant virus stability is good.
Seed culture of viruses safety testing result shows that the vaccine on mouse is safe, no mad dog specific symptom of puppet, does not influence
Grow.Porcine pseudorabies virus gene-deleted vaccine (the PRV/gE that the present invention transforms-/gI-) it is safe, it can be used for
Prepare vaccine.
21d, Bartha-K61, PRV/gE after immune-/gI-Group and DMEM control group mice average weight gains be respectively 4.4g,
4.1g, 4.5g, weightening difference is little, illustrates weightening unrestraint effect of the gene-deleted strain to mouse.Do not examined yet during 14d after immune anti-
Body, PRV/gE during 21d-/gI-Group antibody level is significantly raised, and other groups are still without significant change.Show PRV/gE-/gI-Missing
Strain can induce mouse and produce obvious immune response.After immune 21d poison, PRV/gE are attacked with PRV QD strains-/gI-Group protective rate is obvious
Higher than Bartha-K61 groups, protective rate is respectively 100% and 20%.
The preparation and application of the porcine pseudorabies virus gene-deleted vaccine of embodiment 3
1 material
1.1 seed culture of viruses
Vaccine porcine pseudorabies virus is manufactured, deposit number is：CGMCC No.10266.
1.2 experimental animal
BALB/C small white mouses, purchased from Shandong University's Experimental Animal Center.
1.3 seedling Other Instruments, reagent
There is provided by Shandong Sinder Technology Co., Ltd..
2 methods
2.1 seedling processes
Vero cells are cultivated according to a conventional method, with 5-10PFU virus infected cells, when cytopathy (CPE) is left up to 90%
Virus is harvested when right, puts -80 DEG C of multigelations three times, determines the TCID of virus50.According to the malicious valency of harvest virus liquid, fitted
When dilution, virus liquid after dilution is 1 with protectant volume ratio:1.5, it is sufficiently mixed, wherein sucrose final concentration of 20%,
Gelatin final concentration of 4.8%.Per bottled 2.5mL, freezed in juxtaposition freeze dryer.
2.2 product inspection
2.2.1 character
Appearance color, character and the bottle wall for observing vaccine depart from situation and dissolve situation after adding dilution.
2.2.2 steriling test
By version in 2010《Chinese veterinary pharmacopoeia》Annex method is tested.
2.2.3 mycoplasma is examined
By version in 2010《Chinese veterinary pharmacopoeia》Annex method is tested.
2.2.4 exogenous virus is examined
By version in 2010《Chinese veterinary pharmacopoeia》Annex method is tested.
2.2.5 safety verification
With the BALB/C mice 10 of 6 week old, intramuscular injection 0.2ml (containing 10 plumage parts) vaccine, observe 21, should all be good for
It is living, without any locally or systemically adverse reaction.
2.2.6 efficacy test
Following method, which is appointed, selects one.
2.2.6.1 cellular assay is used
The plumage part indicated by label, is diluted to l plumages part/0.2ml with 10%DMEM by vaccine, remakes 10 times and be serially diluted,
Take 10-2、10-3、10-4、10-5Four dilution factors, are inoculated with the good Vero cells of growth conditions respectively, and each dilution factor is inoculated with 8
Hole, per hole 0.2m1,8 holes are separately taken to be used as control for inoculation 10%DMEM.37 DEG C of incubation CO2Carried out in incubator after being incubated 3,
Lesion situation is observed, TCID is calculated by Reed-Muench methods50, viral level should >=104.0TCID50/0.2ml。
2.2.6.2 examined with mouse
Take 6 week old BALB/C mice 10, every plumage part of intramuscular injection vaccine 1.After 21 days, together with 10 control mices,
Hindlimb muscle injection 104.0TCID50/ only, observe 14.Control group at least 8 death or pseudo- mad dog specific symptom should occur,
Immune group should at least 8 protections.
2.2.7 residual moisture determines
By version in 2010《Chinese veterinary pharmacopoeia》Annex method is carried out.
2.2.8 vacuum determines
By version in 2010《Chinese veterinary pharmacopoeia》Annex method is carried out.
2.2.9 vaccine using effect is examined
15 first 30 age in days piglets are chosen before experiment, 3 groups, every group 5 is randomly divided into and weighs, vaccinate strain respectively
Bartha-K61, gene-deleted strain PRV/gE-/gI-Vaccine and DMEM.Every injection 2mL DMEM of control group, other two groups of hindlimb muscles
Injection 105.0TCID50The vaccine of viral dosage.Carry out within 4th week attacking poison, intramuscular injection 10 after immune7.0TCID50PRV QD strain strains
Virus, clinical symptoms are observed, calculate protective rate situation.
3 results
3.1 viral levels determine
Porcine pseudorabies virus content is 106.5TCID50/0.1ml。
3.2 product inspection results
3.2.1 character
Slightly yellow Sponge Porosity agglomerate, when rocking up and down, sample is easy to depart from bottle wall.It is fast after addition dilution
Instant solution.
3.2.2 steriling test
10 bottles of vaccine grab sample, recover commercial weight with 10%DMEM respectively, every bottle is pressed version in 2010 respectively《Chinese veterinary drug
Allusion quotation》Annex method is tested.Without bacterium, fungus growth.
3.2.3 mycoplasma is examined
5 bottles of vaccine grab sample, recover commercial weight with 10%DMEM respectively and mix, by version in 2010《Chinese veterinary pharmacopoeia》
Annex method is tested.Vaccine grows without mycoplasma.
3.2.4 exogenous virus is examined
Cell toxicant genome is extracted, carries out the PCR identifications of exogenous virus, result is feminine gender, shows vaccine exogenous virus
It is qualified to examine.
3.2.5 safety verification
Vaccine samples 3 bottles, makees appropriate dilution after recovering commercial weight with 10%DMEM respectively, each intramuscular injection 0.2ml vaccines, sees
Examine 21.As a result show, Mice Inoculated is without any adverse reaction, and 10/10 is good for work.
3.2.6 efficacy test
3.2.6.1 cellular assay is used
The plumage part indicated by label, is diluted to l plumages part/0.2ml with 10%DMEM by vaccine, remakes 10 times and be serially diluted,
After inoculating cell TCID is calculated according to Reed-Muench methods50, the results showed that every plumage part is 104.5TCID50.The equal nothing of control mice
The specific clinical symptoms of pseudo- mad dog.
3.2.6.2 examined with mouse
Take 6 week old BALB/C mice 10, every plumage part of intramuscular injection vaccine 1.After 21 days, together with 10 control mices,
Hindlimb muscle injection 104.0TCID50/ only, observe 14.As a result：There is pseudo- mad dog specific symptom in 10 death of control group.
3.2.7 residual moisture determines
Vaccine samples 4 bottles and tested with boulton process.Product test sample residual moisture content 2.0%~
2.7% ,≤4%.It is qualified to illustrate that vaccine residual moisture measure is examined.
3.2.8 vacuum determines
Vaccine is tested with vacuum leak detector respectively.Product test sample is in purple glow.Illustrate vaccine vacuum
It is qualified that measure is examined.
3.2.9 vaccine using effect
To 30 age in days piglets difference immune vaccine strain Bartha-K61, gene-deleted strain PRV/gE-/gI-Vaccine and DMEM, it is immunized
Carry out attacking poison within the 4th week afterwards, attack malicious result and show, PRV/gE-/gI-Group protective rate divides apparently higher than Bartha-K61 groups, protective rate
Wei 100% and 20%.Show the PRV/gE of the present invention-/gI-The immune effect of vaccine clinically is substantially better than now extensively
The Bartha-K61 vaccines used.Moreover, Detection results show, the pseudorabies that PRV/TK-/gE- vaccines are used the present invention
The immune effect of virus (CGMCC No.10266) is significantly better than other vaccines (p ＜ 0.05)；Prove as starting strain
Porcine pseudorabies virus (CGMCC No.10266) has specificity genetically.
Claims (7)
1. a kind of pseudorabies disease vaccine, it is characterised in that described vaccine is made up of antigen and protective agent, wherein antigen bag
Attenuated viral strains made of containing carrying out after virulence gene missing by the Strain that deposit number is CGMCC No.10266；It is described
Virulence gene be gE and gI genes.
2. pseudorabies disease vaccine as claimed in claim 1, it is characterised in that described protective agent is protected for viral vaccine
Agent.
3. pseudorabies disease vaccine as claimed in claim 2, it is characterised in that described protective agent is the water of sucrose and gelatin
Solution.
4. pseudorabies disease vaccine as claimed in claim 3, it is characterised in that the matter of described sucrose and gelatin in vaccine
It is respectively 20% and 4.8% to measure percentage final concentration.
5. pseudorabies disease vaccine as claimed in claim 1, it is characterised in that add antibiotic in described vaccine.
6. pseudorabies disease vaccine as claimed in claim 5, it is characterised in that described antibiotic is penicillin and strepto-
Element.
7. pseudorabies disease vaccine as claimed in claim 6, it is characterised in that described penicillin and the final concentration of streptomysin
Respectively 200 units/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510246482.3A CN104877972B (en) | 2015-05-15 | 2015-05-15 | A kind of dual-gene gene-deleted strain of recombinant porcine pseudorabies poison gE/gI and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510246482.3A CN104877972B (en) | 2015-05-15 | 2015-05-15 | A kind of dual-gene gene-deleted strain of recombinant porcine pseudorabies poison gE/gI and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104877972A CN104877972A (en) | 2015-09-02 |
| CN104877972B true CN104877972B (en) | 2018-01-02 |
Family
ID=53945652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510246482.3A Active CN104877972B (en) | 2015-05-15 | 2015-05-15 | A kind of dual-gene gene-deleted strain of recombinant porcine pseudorabies poison gE/gI and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104877972B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105385666B (en) * | 2015-11-26 | 2019-01-25 | 中国兽医药品监察所 | The building of 5 gene-deleted strain of pseudorabies virus double fluorescence labeling |
| CN106834236A (en) * | 2016-02-23 | 2017-06-13 | 南京农业大学 | PRV variant TK, gE and gI gene delection strain and its application |
| CN107267470A (en) * | 2017-08-08 | 2017-10-20 | 中国农业大学 | A kind of gE plants of PRV gene-deleted strain C1201/ Δs and its application |
| CN109609468B (en) * | 2018-12-10 | 2020-06-30 | 畜科生物工程有限公司 | Six-gene-deleted porcine pseudorabies virus, porcine pseudorabies vaccine and preparation method thereof |
| CN110684746A (en) * | 2019-09-26 | 2020-01-14 | 北京市动物疫病预防控制中心 | Preparation method and detection method of freeze-dried Newcastle disease virus nucleic acid standard substance |
| CN112501133B (en) * | 2020-12-01 | 2022-05-24 | 山东信得科技股份有限公司 | Pseudorabies virus QD strain three-gene deletion weakening strain |
| CN113249341A (en) * | 2021-02-03 | 2021-08-13 | 铜仁职业技术学院 | Porcine pseudorabies virus double-gene deletion strain |
| CN112773892A (en) * | 2021-02-09 | 2021-05-11 | 铜仁职业技术学院 | Porcine pseudorabies virus low virulent strain freeze-dried vaccine |
| CN113502275A (en) * | 2021-06-21 | 2021-10-15 | 江西正邦科技股份有限公司 | Porcine pseudorabies virus strain and application thereof |
| CN114657151B (en) * | 2022-02-25 | 2024-03-12 | 广东海大畜牧兽医研究院有限公司 | Porcine pseudorabies virus gE/gI/TK gene deletion vaccine strain, construction method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1523103A (en) * | 2003-09-08 | 2004-08-25 | 华中农业大学 | Pseudorabies TK*/gE*/gI* gene dificiency mark live vaccine and preparation method thereof |
| CN1940063A (en) * | 2005-09-29 | 2007-04-04 | 华中农业大学 | Pseudo-rabies gE/gI-gene loss poison strain, killed vaccine containing it and use |
| CN103756977A (en) * | 2013-12-11 | 2014-04-30 | 姜平 | gE- and gI-deleted porcine pseudorabies virus variant strain and use thereof |
| CN104059889A (en) * | 2014-03-20 | 2014-09-24 | 中国农业科学院哈尔滨兽医研究所 | Double gene-deleted strain of pseudorabies virus variant, construction method and application thereof |
| CN104152416A (en) * | 2014-01-03 | 2014-11-19 | 中国农业科学院上海兽医研究所 | Pseudorabies virus gene-deleted attenuated strain as well as preparation method and application thereof |
-
2015
- 2015-05-15 CN CN201510246482.3A patent/CN104877972B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1523103A (en) * | 2003-09-08 | 2004-08-25 | 华中农业大学 | Pseudorabies TK*/gE*/gI* gene dificiency mark live vaccine and preparation method thereof |
| CN1940063A (en) * | 2005-09-29 | 2007-04-04 | 华中农业大学 | Pseudo-rabies gE/gI-gene loss poison strain, killed vaccine containing it and use |
| CN103756977A (en) * | 2013-12-11 | 2014-04-30 | 姜平 | gE- and gI-deleted porcine pseudorabies virus variant strain and use thereof |
| CN104152416A (en) * | 2014-01-03 | 2014-11-19 | 中国农业科学院上海兽医研究所 | Pseudorabies virus gene-deleted attenuated strain as well as preparation method and application thereof |
| CN104059889A (en) * | 2014-03-20 | 2014-09-24 | 中国农业科学院哈尔滨兽医研究所 | Double gene-deleted strain of pseudorabies virus variant, construction method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| gl/gE双基因缺失伪狂犬病病毒变异株的构建和免疫效力评价;王春花;《中国优秀硕士学位论文全文数据库农业科技辑》;20141115(第11期);D050-62 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104877972A (en) | 2015-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104877972B (en) | A kind of dual-gene gene-deleted strain of recombinant porcine pseudorabies poison gE/gI and its application | |
| CN104826103B (en) | A kind of porcine pseudorabies virus vaccine | |
| CN104830810B (en) | A kind of gene-deleted strains of recombinant porcine pseudorabies poison TK/gE/gI tri- | |
| CN104862286B (en) | Porcine pseudorabies virus gene-deleted strain, vaccine composition and its preparation method and application | |
| CN102994458B (en) | Porcine pseudorabies virus virulent strain, and gene deletion vaccine strain thereof and applications thereof | |
| CN109439634B (en) | Pseudorabies virus gene engineering attenuated vaccine strain and application thereof | |
| CN104805060B (en) | A kind of pseudorabies virus and its application | |
| CN101457215B (en) | Recombinant porcine pseudorabies virus-porcine propagate and breath complex virus-porcine circovirus genetic engineering strain and application | |
| CN107815441A (en) | A kind of II type Pseudorabies virus attenuated strain and its preparation method and application | |
| CN112500458B (en) | Novel variant subunit vaccine of chicken infectious bursal disease virus, preparation method and application thereof | |
| CN109136198B (en) | Recombinant fowl pox virus live vector vaccine for expressing chicken infectious anemia virus VP1 and VP2 genes | |
| CN107384874A (en) | Pseudorabies virus epidemic strain gI/gE gene deletion mutants and structure and application | |
| CN111632137A (en) | Triple vaccine for feline calicivirus disease, feline infectious rhinotracheitis and feline panleukopenia as well as preparation method and application thereof | |
| CN113862230A (en) | Porcine pseudorabies virus gene deletion strain, vaccine composition, preparation method and application thereof | |
| CN106834236A (en) | PRV variant TK, gE and gI gene delection strain and its application | |
| CN103087996A (en) | Recombinant porcine reproductive and respiratory syndrome virus as well as preparation method and application thereof | |
| CN114854697B (en) | Trivalent inactivated vaccine of porcine rotavirus G4-G5-G9 and preparation method and application thereof | |
| CN110387355A (en) | Express recombinant porcine pseudorabies Strain, the vaccine and its preparation method and application of pig circular ring virus Cap protein gene | |
| CN110527669A (en) | A kind of porcine pseudorabies virus gene delection strain and its construction method and application | |
| CN111876391A (en) | Feline panleukopenia virus FPV BJ05 strain and application thereof | |
| CN103509761B (en) | Recombinant porcine pseudorabies virus strain used for expression of porcine circovirus type II (PCV2) ORF2 gene, and preparation method thereof | |
| CN104059889A (en) | Double gene-deleted strain of pseudorabies virus variant, construction method and application thereof | |
| CN110305852A (en) | Express the building of Porcine epidemic diarrhea virus S1 genetic recombination pseudorabies virus | |
| CN105802921B (en) | Recombinant pseudorabies virus variant strain for expressing classical swine fever virus E2protein and construction method and application thereof | |
| CN112538464A (en) | Reverse genetic vaccine strain rHN20 of avian adenovirus serotype 4 as well as construction method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Mingyi Inventor after: Li Jiaqi Inventor after: Yu Zekun Inventor after: Luan Zhifang Inventor after: Li Sifei Inventor after: Ma Lizhao Inventor after: Li Xiaolin Inventor after: Wu Haiyan Inventor after: Zhu Yanli Inventor after: Li Yanfeng Inventor after: Shan Xueqiang Inventor after: Liu Yang Inventor after: Liu Shanshan Inventor after: Sun Hualu Inventor after: Sun Wei Inventor after: Yan Ruijuan Inventor after: Ge Dong Inventor after: Zhang Lun Inventor before: Li Mingyi Inventor before: Liu Shanshan Inventor before: Sun Wei Inventor before: Liu Yang Inventor before: Li Xiaolin Inventor before: Zhao Hang Inventor before: Li Yanfeng Inventor before: Ge Dong Inventor before: Li Jiaqi |
|
| CB03 | Change of inventor or designer information | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A recombinant porcine pseudorabies virus gE / GI double gene deletion strain and its application Effective date of registration: 20211222 Granted publication date: 20180102 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2021980015708 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221223 Granted publication date: 20180102 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2021980015708 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Recombinant Pseudorabies Virus gE/gI Double Gene Deletion Strain and Its Application Effective date of registration: 20230608 Granted publication date: 20180102 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2023980043376 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20180102 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2023980043376 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |